ReviewCancer medicine2019
Ovarian cancer: Current status and strategies for improving therapeutic outcomes.
Review in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05610501 (Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.), which is not on this map. Cited by 231 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.
Who cites it
231 citing papers in PubMed, 2 syntheses or guidelines pooled it, 438 citations in OpenAlex.
- The role of ultrasound-guided tru-cut biopsy in ovarian cancer: a systematic review of its safety, adequacy, and accuracy with meta-analysis of diagnostic performance.Journal of ovarian research · 2025Pooled it
- Evolution of Immunotherapy for Ovarian Cancer from a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics.Frontiers in oncology · 2022Pooled it
- Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer.Cancer gene therapy · 2026Article
- STAT3 Inhibitor Suppresses CCL2-dependent Recruitment and M2 Polarization of Tumor-associated Macrophages to Enhance Antitumor Immunity in Ovarian Cancer.Applied biochemistry and biotechnology · 2026Article
- Refining OVCAR-3 xenograft models of peritoneal carcinomatosis in nu/nu mice: Comparative intraperitoneal implantation strategies and the role of basement membrane matrix.Animal models and experimental medicine · 2026Article
- Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.Cell biomaterials · 2026Article
- Ultrasonography-Guided Core Needle Biopsy in the Diagnostic Pathway of Pelvic Tumors.JAMA network open · 2026Article
- Cooperative Suppression of Ovarian Cancer Growth by 1,25-Dihydroxyvitamin DCancer medicine · 2026Article
- Rosmarinic Acid Sensitizes Ovarian Cancer Cells to Gemcitabine Through Oxidative Stress-Associated Apoptotic and Antiproliferative Responses.International journal of molecular sciences · 2026Article
- Multi-scale evidence chain: Linking environmental BPA exposure to ovarian cancer through integrated omics and experimental models.Translational oncology · 2026Article
- Podocalyxin may be down-regulated by progesterone in high grade serous ovarian cancer spheroids to increase responsiveness to carboplatin and NK cells.BMC cancer · 2026Article
- Catechin-Folate nano-niosomes from Osbeckia parvifolia Arn. induce apoptotic cell death in Ovarian cancer.Scientific reports · 2026Article
- Amino acid appended supramolecular self-associating amphiphiles demonstrate dual activity against both MRSA and ovarian cancer.Chemical science · 2026Article
- Plasma cell-free DNA 5-hydroxymethylcytosine signatures as predictive biomarkers for platinum resistance and prognosis in epithelial ovarian cancer.Journal of ovarian research · 2026Article
- Ferrodoxin 1 (FDX1) drives paclitaxel resistance in ovarian cancer via copper metabolism and ULK1/ATG13-mediated autophagy: overcome by pH/ROS-responsive PPD/PDP@si-FDX1 nanomicelles.Journal of experimental & clinical cancer research : CR · 2026Article
- Ovarian Cancer Mortality Predictors in Public Oncology Centers, Addis Ababa, Ethiopia: A Case-Control Study.Cancer reports (Hoboken, N.J.) · 2026Article
- Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative.International journal of molecular sciences · 2026Article
- A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
- Nanoparticle based siRNA therapeutics for ovarian cancer overcoming drug resistance and future directions.Discover nano · 2026Review
- HMGB1 Assists in Overcoming Cisplatin Resistance in Chemoresistant Human Ovarian Cancer Cells.Molecular carcinogenesis · 2026Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced-stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early-stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2-years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality-of-life. A procedure that has been studied to help reduce the morbidity rate involves pre-sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum-based agents are effective due to their increased response to platinum-based chemotherapy in relapsed cases. These chemo-drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.